PATENT CLAIM ANALYSIS

Application Number: 16177149
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-05
Patent Classification: ["514", "300000"]

Abstract:
Diazanaphthalene compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a diazanaphthalene compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, inflammation, auto-immune diseases and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.

Claim (Index 19):
The method of  claim 18 , wherein the cancer is selected from the group consisting of: osteoma, hemangioma, granuloma, xanthoma, osteitis deformans, meningioma, meningiosarcoma, and gliomatosis, astrocytoma, medulloblastoma, glioma, ependymoma, germinoma (pinealoma), glioblastoma multiform, oligodendroglioma, oligodendrocytoma, schwannoma, retinoblastoma, and congenital tumors, neurofibroma, meningioma, glioma, and sarcoma.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 97.0
- Lexical Diversity: 1.45902
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15498990', '15749587', '15749923', '15749910', '15749922']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8314523073508926
- 35 USC 102 Novelty (BERT): 0.5666589280874214
- Combined Prediction Score: 0.8049729694245454
- Mean Citation Score: 444.7209820000001
- Max Citation Score: 527.2941
- Similarity Product: 331.7729351981164

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test